skip to Main Content

South San Francisco, CA, April 30, 2018 – FlemingMartin is pleased to announce that MyoKardia (NASDAQ: MYOK), a company pioneering a precision approach to serious, neglected and rare cardiovascular diseases, has hired Carmen Merritt as a new Senior Director, Human Resources Business Partner.

Ms. Merritt brings a strategic leadership background to MyoKardia from her impressive career as an HR professional across the biotechnology industry with Five Prime Therapeutics, Onyx Pharmaceuticals, Novartis, Amgen and Ocular Sciences. She has experience serving as an HRBP to Technical Operations, Quality, and R&D, along with a passion for organizational development and coaching. Throughout her career, Ms. Merritt has thrived at both small and large life sciences companies and has a proven track record across all human resource disciplines. Ms. Merritt holds a BA in Economics from the University of California, Berkeley.

 

MyoKardia (NASDAQ: MYOK) is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.

 

FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms and CEOs of companies to build successful execution-focused management teams. FlemingMartin focuses in the Technology, Manufacturing, and Consumer Products & Services industries. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.

Back To Top